KMDA 6-K SEC Filing Analysis

Latest settled — T+5d

KMDA ▼ -6.88% at T+5d

LONG call ✗ call lost -6.88% · α vs SPY -4.13% · entry $7.70 → $7.17

Next anchor: T+20d in 17d

Currently $7.44 · -3.38% from $7.70 entry

Entry anchored
May 29, 03:57 PM ET
via Databento tick

T+1d

-2.47%

call -2.47% · α -2.61%

$7.51

settled 11d ago

T+5d

-6.88%

call -6.88% · α -4.13%

$7.17

settled 5d ago

T+20d

—

call — · α —

—

in 17d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Kamada announced FDA approval of its new in-house RFFIT laboratory for rabies potency testing, which supports the manufacturing of KEDRAB and KAMRAB. The lab is expected to improve operational efficiencies and reduce reliance on external testing for its leading rabies franchise, which generated over $70 million in 2025 sales.

Actionable Insight

The FDA approval of an in-house RFFIT lab is a modest positive for Kamada's rabies franchise, potentially improving margins and reducing supply chain risk. Monitor for any future guidance updates or margin improvements in upcoming quarterly reports.

Key Facts

FDA approved Kamada's new in-house RFFIT laboratory for rabies virus neutralization testing.
The lab is located at Kamada's Beit Kama, Israel plant and is one of a limited number worldwide capable of such tests.
The lab was also approved by Health Canada and the Israeli Ministry of Health prior to FDA approval.
In 2025, Kamada's sales of KEDRAB and KAMRAB totaled over $70 million.
The lab supports manufacturing of KEDRAB and KAMRAB from plasma collection to final product release.

Financial Impact

Operational efficiency gains on a franchise generating over $70 million in annual sales; no specific cost savings or revenue impact quantified.

operational efficiencycost of goods sold

Risk Factors

No quantified financial impact from the lab approval; benefits may be gradual.
Operational execution risk in transitioning testing from external to in-house capabilities.
Geopolitical risk from the lab's location in Israel.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

89% bullish (9 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
6-K Filing (Primary)	0001213900-26-063140
Document: ea0292886-6k_kamada.htm	0001213900-26-063140
Document: 0001213900-26-063140-index-headers.html	0001213900-26-063140
Document: 0001213900-26-063140-index.html	0001213900-26-063140
Document: 0001213900-26-063140.txt	0001213900-26-063140

7 reports for KMDA

T+1T+5T+20T+60

100% Hit rate 4 of 4 directional calls best @ T+5▲ +3.31%May 13, 2026

Filters

Reports for KMDA — sortable, filterable
	Type				Now
Jun 1, 2026 11d ago	6-K BULLISH ★ 5/10	$7.70 $7.17	▼ −6.88%	▼ −4.13%	$7.44 (−3.38%)
May 13, 2026 4w ago	Press Release BEARISH ★ 7/10	$7.86 $7.60	▲ +3.31%	▲ +2.15%	$7.44 (+5.34%)
Mar 31, 2026 10w ago	6-K NEUTRAL ★ 3/10	$8.34 $8.47	▲ +1.56%	▼ −2.39%	$7.44 (−10.79%)
Mar 26, 2026 11w ago	6-K BULLISH ★ 7/10	$8.22 $8.47	▲ +3.04%	▲ +1.41%	$7.44 (−9.49%)
Mar 26, 2026 11w ago	Press Release BULLISH ★ 7/10	$8.22 $8.47	▲ +3.04%	▲ +1.41%	$7.44 (−9.49%)
Mar 11, 2026 13w ago	Press Release BULLISH ★ 8/10	$8.30 $8.34	▲ +0.47%	▲ +2.66%	$7.44 (−10.35%)
Mar 11, 2026 13w ago	Press Release NEUTRAL ★ 4/10	$8.30 $8.34	▲ +0.47%	▲ +2.66%	$7.44 (−10.35%)

US Market Status

Market Closed — Opens Mon (53h 15m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access